FDA announces massive recall of blood pressure medication due to potentially carcinogenic substance
On the reason for the recall, the agency explained that it was due to the "presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit."
FDA building.
The Food and Drug Administration (FDA) reported that drug makers have recalled more than half a million bottles of the blood pressure drug prazosin hydrochloride over concerns that it may contain a carcinogenic chemical.
According to the information, New Jersey-based Teva Pharmaceuticals USA and Amerisource Health Services, a drug distributor, voluntarily recalled more than 580,000 bottles of prazosin capsules of varying strengths earlier this month.
On the reason for the recall, the agency explained that it was given for the "presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit."
N-nitrosamine impurities
According to the Associated Press, doctors prescribe prazosin as a drug that helps relax blood vessels and lower blood pressure. In addition, in some cases it is used to treat nightmares and other sleep problems associated with post-traumatic stress disorder.
LATEST
